By Bachem AG
To get in touch with Bachem AG, simply fill out the form below.
Subscribe to Supplier
Bachem reveals impressive growth figures behind award nomination
Bubendorf, Switzerland: –Peptide technology specialist Bachem AG has detailed the impressive growth in its workforce that was a significant factor in it being nominated for a 2021 Swiss Biotech Association Success Story Award.
Despite being a mature company with an almost 50 year history, Bachem is currently showing growth rates normally associated with start-up companies, driven by surging demand across its whole product portfolio of peptides, oligonucleotides and complex organic molecule active pharmaceutical ingredients (APIs), along with innovative biochemicals and exclusive custom syntheses for research.
Fast expanding workforce
“The creation of jobs in Switzerland is one of the reasons for our nomination as a ‘Swiss Biotech Success Story,” the company commented.
“It all started when our company was founded in 1971 by Peter Grogg. Fast forward to 2019, we were at 820 full time equivalent posts (FTEs) in Switzerland) and by end of June 2020, we were at 917 FTEs,” said Bachem.
Over the past half year, the Bachem workforce grew by 12 per cent, meaning that more than one in ten Bachem employees is doing a job created during 2020.
“For a start-up, these numbers are probably average, but we are celebrating our 50th anniversary next year and are planning to grow even further to double our production capabilities in Bubendorf until 2027,” Bachem commented.
Educating the next generation
“We feel honored to be nominated for the creation of jobs, but for us, it is even more important to pass on our knowledge by educating the next generation. Currently, a bit more than four per cent of our employees are apprentices who are learning on the job while being in school. Luckily for us, most of them decide to stay at Bachem after receiving their diploma,” said Bachem.
The Swiss Biotech Association’s annual Swiss Biotech Success Stories showcase valuable accomplishments by the biotech industry in Switzerland and honor individual people who have made important and sustainable contributions to the industry.
The 2021 award nomination recognizes Bachem’s success story as a highly innovative company and founder Dr. Peter Grogg for his vision, his flair for entrepreneurial thinking and courage in taking risks. Bachem has been shortlisted for a number of accomplishments, including achieving lasting impact, creating jobs in Switzerland and becoming an enabler for the biotech industry.
Final winners will be announced in April 2021.
The Swiss based Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of pepTides, oligonucleoTides and complex organic molecules as active pharmaceutical ingredients (APIs). A comprehensive catalog of innovative biochemicals for research and exclusive custom syntheses for research labs complete its service portfolio.
With 50 years of experience, headquartered in Switzerland with subsidiaries in Europe, the US and Asia, the group has a global reach and shows total commitment to quality, innovation and partnership to its customers worldwide.
Under its banner Leading Partner in Tides, Bachem prioritizes continuous investment in R&D on chemistries and technologies as crucial for future success. Its ever-increasing knowledge of complex proteins and peptides derives from ongoing research in proteomics, as well as progress in mass spectrometry, synthesis and ligation technologies, complemented by collaboration with external research institutions.
Bachem has five production sites in the US, UK and Switzerland along with research level production and full cGMP manufacturing facilities on both continents. These provide capacity to produce APIs, key intermediates, small molecule generics, and new chemical entities (NCEs) at preclinical, clinical and production scales.
Further information at: www.bachem.com
About Swiss Biotech Association
Founded in 1998, the Swiss Biotech Association represents the interests of the Swiss biotechnology industry, collaborating with numerous partners and life science clusters globally under the brand Swiss Biotech™.
To support its members in a competitive market, the Zurich-based Association works to secure favorable framework conditions and facilitate access to talents, novel technologies and financial resources.
Its core mission is to ensure that the value generated by the Swiss biotech industry continues to grow and that the industry contributes to the well-being of the socio-economic ecosystem thereby enabling Switzerland to be a key player at the forefront of bioscience innovation.
Further information at: http://www.swissbiotech.org/